Press Releases

  • CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference
    18-11-21 / Press Release
    Read more
  • University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator
    18-11-07 / Press Release
    Read more
  • CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the 2018 Society for Immunotherapy of Cancer Annual Meeting
    18-11-07 / Press Release
    Read more
  • CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA
    18-10-23 / Press Release
    Read more
  • CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations
    18-06-12 / Press Release
    Read more
  • CureVac Announces New Management Structure
    18-05-08 / Press Release
    Read more
  • CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA
    18-03-22 / Press Release
    Read more
  • CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria
    18-02-13 / Press Release
    Read more
  • CureVac Expands Intellectual Property Position that Significantly Improves Protein Expression for its mRNA-Based Vaccines and Therapeutics
    18-01-24 / Press Release
    Read more
  • CureVac Highlights Key 2018 Corporate Milestones and Outlook
    18-01-10 / Press Release
    Read more
  • CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics
    18-01-04 / Press Release
    Read more
  • CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs
    17-11-13 / Press Release
    Read more
  • 5th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration
    17-11-06 / Press Release
    Read more
  • CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics
    17-10-29 / Press Release
    Read more
  • CureVac Initiates Phase I Clinical Trial of RNAdjuvant® Candidate as Intratumoral Therapy for Solid Tumors
    17-10-27 / Press Release
    Read more
  • Publication in npj Vaccines Demonstrates CureVac’s RNActive® Vaccine is Superior to Licensed Vaccines
    17-10-23 / Press Release
    Read more
  • Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
    17-10-18 / Press Release
    Read more
  • Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors
    17-08-15 / Press Release
    Read more
  • 5th International mRNA Health Conference to Showcase Tremendous Advances in the Development of mRNA Drugs
    17-07-31 / Press Release
    Read more
  • CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine
    17-07-26 / Press Release
    Read more
  • CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies
    17-07-20 / Press Release
    Read more
  • CureVac Expands GMP Production Capacities for RNA Products
    17-06-26 / Press Release
    Read more
  • CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines
    17-06-13 / Press Release
    Read more
  • CureVac to Present at Upcoming International Investor Conferences
    17-05-19 / Press Release
    Read more
  • CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary
    17-05-02 / Press Release
    Read more
  • CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group
    17-01-20 / Press Release
    Read more
  • CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference
    17-01-11 / Press Release
    Read more
  • CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017
    16-12-28 / Press Release
    Read more
  • Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma (HCC) Patients and Healthy Subjects to the RNA-based adjuvant
    16-12-05 / Press Release
    Read more
  • CureVac Secures an Additional $29.5 Million From Two New Investors
    16-11-08 / Press Release
    Read more
  • CureVac Receives Broad Patent for RNAntibody® Technology
    16-11-08 / Press Release
    Read more
  • CureVac Appoints Pierre Kemula as Chief Financial Officer
    16-10-11 / Press Release
    Read more
  • Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines
    16-07-14 / Press Release
    Read more
  • CureVac Appoints Leading Experts to its Scientific Advisory Board
    16-03-30 / Press Release
    Read more
  • CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion
    16-03-18 / Press Release
    Read more
  • CureVac announces “MERAN” has been approved by the World Health Organization as suffix for mRNA drug substances
    16-02-18 / Press Release
    Read more
  • CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference
    16-01-06 / Press Release
    Read more
  • CureVac raises $110 Million in a private placement
    15-11-03 / Press Release
    Read more
  • IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates
    15-09-10 / Press Release / News
    Read more
  • CureVac Establishes U.S. Operations in Cambridge, MA
    15-09-10 / Press Release / News
    Read more
  • CureVac & Bill & Melinda Gates Foundation - Collaboration to Develop mRNA Vaccines Expands
    15-08-04 / Press Release / News
    Read more
  • CureVac Announces Phase I/IIa Clinical Study Data
    15-07-07 / Press Release / News
    Read more
  • CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs
    15-06-24 / Press Release
    Read more
  • The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology
    15-03-05 / Press Release / News
    Read more
  • Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
    14-09-18 / Press Release
    Read more
  • CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine
    14-07-01 / Press Release
    Read more
  • CureVac Wins Two Million EUR from Inaugural European Commission Vaccine Prize
    14-03-10 / Press Release
    Read more
  • CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment
    13-12-16 / Press Release
    Read more
  • 1st International mRNA Health Conference in Tübingen Heralds a New Era in Modern Medicine
    13-11-05 / Press Release
    Read more
  • CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer
    13-11-04 / Press Release
    Read more
  • CureVac to Collaborate with Janssen on Development of mRNA-Based Influenza Vaccine
    13-10-03 / Press Release
    Read more
  • CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer
    13-03-27 / Press Release
    Read more
  • Data Published in Nature Biotechnology
    12-11-26 / Press Release
    Read more
  • CureVac, Sanofi Pasteur and In-Cell-Art collaborate on a $33.1 million project
    12-11-15 / Press Release
    Read more
  • CureVac Secures €80 Million in Series D Financing
    12-09-18 / Press Release
    Read more
  • CureVac presents clinical results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC)
    11-11-07 / Press Release
    Read more

Your contact

Matthew Beck
Vice President Investor Relations
T: +1 917 415 1750
contact via e-mail